With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

The biotech, which has raised more than $140 million over several investment rounds in the last few years from the likes of ...

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...

AI drug discovery firm Isomorphic Labs has completed the company’s first external funding round since its 2021 founding ...

Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...

Apollomics has sold the rights to its lead c-MET inhibitor in Asia, excluding Greater China, to Taiwan’s LaunXP Biomedical ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the ...

GE HealthCare has raised the curtain on a new CT system with features designed specifically for addressing cardiovascular ...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet now that one of the treatments from the deal ...